This study is designed to assess the pharmacokinetic properties, safety, tolerability, and immunogenicity of ABBV-142 and determine whether predicted efficacious exposures can be safely achieved in humans.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Number of Participants with Adverse Events (AEs)
Timeframe: Up to Day 120
Maximum Observed Serum Concentration (Cmax) of ABBV-142
Timeframe: Up to Day 120
Time to Cmax (Tmax) of ABBV-142
Timeframe: Up to Day 120
Area Under the Serum Concentration-time Curve (AUC) of ABBV-142 from Time 0 to the Time of Last Measurable Concentration (AUCt)
Timeframe: Up to Day 120
AUC of ABBV-142 from Time 0 to Infinity (AUCinf)
Timeframe: Up to Day 120
Terminal Phase Elimination Rate Constant (β) of ABBV-142
Timeframe: Up to Day 120
Terminal Phase Elimination Half-life (t1/2) of ABBV-142
Timeframe: Up to Day 120
Dose Normalized Cmax of ABBV-142
Timeframe: Up to Day 120
Dose Normalized AUC of ABBV-142
Timeframe: Up to Day 120